Related Experiment Video
Updated: Jun 28, 2026
09:57
Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
Published on: June 28, 2021
Protein- and DNA-based active immunotherapy targeting interleukin-13 receptor alpha2
Akiva Mintz1, Denise M Gibo, A B Madhankumar
1Brain Tumor Center of Excellence, Department of Neurosurgery & Radiology, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1082, USA. akiva.mintz@systrend.com
Cancer Biotherapy & Radiopharmaceuticals
|November 4, 2008
Summary
Targeting interleukin-13 receptor alpha 2 (IL13Ralpha2) with protein or DNA vaccines completely protected mice against high-grade astrocytoma (HGA) growth. This immunotherapy approach shows promise for eradicating residual HGA cells and preventing recurrence.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- High-grade astrocytoma (HGA) is a fatal brain tumor with limited treatment options.
- Interleukin-13 receptor alpha 2 (IL13Ralpha2) is highly overexpressed in HGAs but not in most normal tissues, making it a promising therapeutic target.
Purpose of the Study:
- To evaluate the efficacy of IL13Ralpha2-targeted protein and DNA vaccines against HGA in a murine model.
- To assess the potential of IL13Ralpha2 as a target for anti-HGA immunotherapy.
Main Methods:
- Development of a G26-IL13Ralpha2-expressing syngeneic murine glioma model.
- Immunization of mice with recombinant IL13Ralpha2 protein or a DNA expression vector targeting IL13Ralpha2.
- Challenge of immunized mice with IL13Ralpha2-expressing G26 tumors.
Main Results:
- Both protein and DNA vaccines targeting IL13Ralpha2 conferred complete protection against glioma growth and mortality in mice.
- Recombinant protein vaccines elicited detectable anti-IL13Ralpha2 antibodies, while DNA vaccines did not.
- Control mice without vaccination developed tumors and succumbed to the disease.
Conclusions:
- IL13Ralpha2-targeted protein and DNA immunotherapies are effective in preventing HGA growth in a preclinical model.
- These findings support the clinical potential of IL13Ralpha2-targeted vaccines for eradicating residual HGA cells and improving patient outcomes.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...